Health TrialsbyHealthPanel

Effect of TMS Treatment on Defense Mechanisms and Functionality in Patients With Depression

ConditionMajor Depressive Disorder (MDD)
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorNamik Kemal University

About this trial

This prospective observational study aims to evaluate changes in psychological defense mechanisms in patients with non-psychotic major depressive disorder (MDD) undergoing repetitive Transcranial Magnetic Stimulation (rTMS) therapy. The study investigates whether rTMS induces a shift from immature to more mature defense mechanisms and assesses how these changes relate to improvements in depressive symptom severity, anxiety levels, and overall functionality at baseline, 1-month, and 3-month follow-ups.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age between 18 and 65 years

Diagnosis of major depressive disorder without psychotic features according to DSM-5 criteria

Confirmation of diagnosis via SCID-5

Major depressive disorder as the primary reason for admission

Disqualifiers

Presence of contraindications for TMS (e.g., metallic implants)

Known active psychotic symptoms

History of TMS treatment in the past 3 months

Presence of known organic brain syndrome, neurological, or major systemic medical conditions

Trial design

Design model

Single group

Treatments tested in this trial

  • Transcranial Magnetic Stimulation

    Device

    TMS protocol administered to patients with major depressive disorder.

Treatment groups

50 Participants
are divided into 1 treatment group
Group A: TMS Treatment GroupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Change in Defense Mechanisms (Defense Style Questionnaire - DSQ)

Evaluates shifts in mature, neurotic, and immature psychological defense mechanism styles in patients with major depressive disorder following TMS treatment.

Time frame
Baseline, 1 month, and 3 months
2

Change in Disability and Functionality (World Health Organization Disability Assessment Schedule 2.0 - WHODAS 2.0)

Evaluates level of functional disability across six domains (understanding/communicating, mobility, self-care, getting along, life activities, participation).

Time frame
Baseline, 1 month, and 3 months

Secondary outcomes

1

Change in Anxiety Symptom Severity (Hamilton Anxiety Rating Scale - HAM-A)

Assesses psychic and somatic anxiety symptom severity.

Time frame
Baseline, 1 month and 3 months
2

Change in Depressive Symptom Severity (Hamilton Depression Rating Scale - HAM-D)

Assesses the severity of depressive symptoms

Time frame
Baseline, 1 month, and 3 months
3

Change in Clinical Global Impression (CGI)

Measures overall illness severity and clinical improvement.

Time frame
Baseline, 1 month, and 3 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Namik Kemal University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: